MedTrace Logo

To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107

NCT06816719 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-02-10

No results posted yet for this study

Summary

The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0106 and C2101 and administration of JW0107 in healthy volunteers under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Treatment A: JW0106 1 tablet + C2101 1 tablet

* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101 * Administration orally with 150 mL of water under fasting conditions

DRUG

Treatment B: JW0107 1 tablet

* Administration alone of 1 tablet of JW0107 * Administration orally with 150 mL of water under fasting conditions

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2024-11-02
Completion
2024-11-12

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06816719 on ClinicalTrials.gov